Analysts expect Cardinal Health to report consensus revenue of $66.96 billion and earnings of $2.92 per share, with the current stock price of $254.69 trading below the average analyst target of $270.69.
Investors are primarily focused on the performance of the Pharmaceutical and Specialty Solutions segment following the pivotal extension of the company's distribution agreement with CVS Health through 2032.
While sustained demand for specialty drugs and strong generic program performance are anticipated to drive the bottom line, the Medical segment faces ongoing headwinds from commodity and fuel cost pressures. This report marks the first major test of management’s fiscal 2027 guidance, which conservatively assumes a cooling in pharmaceutical demand relative to the record growth seen in the prior year.